KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Share-based Compensation readings, the most recent being $21.0 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 2.27% to $21.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $82.1 million, a 27.73% decrease, with the full-year FY2025 number at $81.5 million, down 27.41% from a year prior.
  • Share-based Compensation hit $21.0 million in Q4 2025 for Ginkgo Bioworks Holdings, up from $18.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.6 billion in Q4 2021 to a low of $118000.0 in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $39.5 million (2024), compared with a mean of $198.2 million.
  • Biggest five-year swings in Share-based Compensation: surged 1348422.03% in 2021 and later tumbled 93.2% in 2022.
  • Ginkgo Bioworks Holdings' Share-based Compensation stood at $1.6 billion in 2021, then tumbled by 93.2% to $108.2 million in 2022, then plummeted by 60.4% to $42.8 million in 2023, then crashed by 52.0% to $20.6 million in 2024, then rose by 2.27% to $21.0 million in 2025.
  • The last three reported values for Share-based Compensation were $21.0 million (Q4 2025), $18.1 million (Q3 2025), and $22.5 million (Q2 2025) per Business Quant data.